Anti-GM1 IgA antibodies in Guillain-Barré syndrome.
Serum anti-GM1 IgA antibodies were detected in 15 of 53 (28%) patients with the acute Guillain-Barré syndrome (GBS) and in one of 26 (4%) patients with other neurological diseases. Although nine GBS patients had anti-GM1 IgA titers of 1:200 or less, six patients had titers of 1:800 or more. Some GBS patients with anti-GM1 IgA antibodies also had antibodies against GD1b or GM2 or both. The presence of markedly elevated anti-GM1 IgA was associated with a poor clinical outcome at 6 and 12 months following onset of the GBS. The possible pathogenetic role of anti-GM1 IgA antibodies remains to be established.
Ilyas
A A
AA
Department of Neurosciences, University of Medicine and Dentistry of New Jersey - New Jersey Medical School, Newark 07103.
Mithen
F A
FA
Chen
Z W
ZW
Cook
S D
SD
D000906:Antibodies / Q000032:analysis* / Q000276:immunology; D005677:G(M1) Ganglioside / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis* / Q000276:immunology; D008124:Locomotion; D011129:Polyradiculoneuropathy / Q000276:immunology* / Q000503:physiopathology
D000906:Antibodies; D007070:Immunoglobulin A; D005677:G(M1) Ganglioside